Reimbursement Processes for Keytruda in Israel, UK, and Australia

By Staff Writer

February 26, 2023

Introduction:

New cancer therapies, such as pembrolizumab, come with high costs, presenting a unique challenge for resource allocation decisions across nations and healthcare systems. Developed countries with national universal health insurance coverage have established different methods. Time to Reimbursement of Pembrolizumab and other oncology treatment are of utmost importance for high level of care. These methods orderly and transparently assess new technologies before adding them to their list of reimbursed services. This process, known as the “fourth hurdle”, is a stage after a country registers the technology. Here, the new technology must show value for money. It also needs to prove its effectiveness and safety before it can qualify for reimbursement from public funds. 

International Approaches:

This research utilises a comparative approach, examining the reimbursement process for pembrolizumab, a cancer treatment drug, in three different healthcare systems: The National Institute for Health and Care Excellence (NICE) in the United Kingdom (UK), the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, and the National Advisory Committee for the Basket of Health Services in Israel. Data were collected from publicly available websites and relevant literature.

Time to Reimbursement of Pembrolizumab:

The research found significant differences in time to reimbursement in these countries, with Israel approving two conditions earlier than the UK and Australia. This paper suggests that unique healthcare policies and systems in these countries could account for these differences.

Conclusion:

The study concludes by suggesting the need for a debate on how to encourage earlier access to necessary and life-saving cancer treatments in countries where the reimbursement process is longer. The most important challenge was budget limitations among many factors that are taken into account in the reimbursement process, and length of time from registration to reimbursement in the public health system of each country.

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.